At the time of writing, Beam Therapeutics Inc [BEAM] stock is trading at $34.55, up 2.55%. An important factor to consider is whether the stock is rising or falling in short-term value. The BEAM shares have gain 21.91% over the last week, with a monthly amount glided 25.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on October 09, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. Previously, BofA Securities upgraded its rating to Buy on March 28, 2025, and kept the price target unchanged to $42. On March 10, 2025, upgrade upgraded it’s rating to Sector Outperform but maintained its price target of $40 on the stock. Cantor Fitzgerald upgraded its rating to an Overweight. Leerink Partners upgraded its rating to an Outperform and raised its price target to $39 on November 06, 2024. In a note dated July 23, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $80 on this stock.
For the past year, the stock price of Beam Therapeutics Inc fluctuated between $13.52 and $36.44. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $34.55 at the most recent close of the market. An investor can expect a potential return of 0.35% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
According to Beam Therapeutics Inc [NASDAQ:BEAM], the company’s sales were 55.70M for trailing twelve months, which represents an -32.03% plunge. Gross Profit Margin for this corporation currently stands at -6.39% with Operating Profit Margin at -8.37%, Pretax Profit Margin comes in at -7.44%, and Net Profit Margin reading is -7.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.43 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Beam Therapeutics Inc [NASDAQ:BEAM] has a current ratio of 6.02. On the other hand, the Quick Ratio is 6.02, and the Cash Ratio is 1.47. Considering the valuation of this stock, the price to sales ratio is 62.94, the price to book ratio is 3.63.
Transactions by insiders
Recent insider trading involved Emany Sravan Kumar, Chief Financial Officer, that happened on Dec 31 ’25 when 6294.0 shares were sold. Chief Legal Officer, Bellon Christine completed a deal on Dec 31 ’25 to sell 1254.0 shares. Meanwhile, FMR LLC sold 459.0 shares on Oct 27 ’25.
